Common diabetes drug could halt devastating kidney disease
NCT ID NCT06090227
Summary
This study is testing whether adding metformin, a common diabetes medication, to standard care can help protect specialized kidney cells called podocytes in people with Focal Segmental Glomerulosclerosis (FSGS). FSGS is a serious kidney disease that often progresses to kidney failure. Researchers will enroll 30 adults to see if metformin reduces cell injury markers better than a placebo over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Contact
Contact
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.